Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Ilaris® (canakinumab) – Expanded indication
June 16, 2020 - The FDA announced the approval of Novartis’ Ilaris (canakinumab), for the treatment of active Still’s disease, including Adult-Onset Still’s Disease (AOSD) in patients aged 2 years and older.
